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INTRODUCTION
Gene expression needs to be tightly regulated as the
specific pattern of gene activation or repression is deci-
sive for establishing fates. The gene expression program
of a cell is controlled by the activities and the interac-
tions of the epigenetic regulatory machinery and se-
quence-specific transcription factors. The epigenetic
machinery consists of enzymes that post-translationally
modify histone proteins, such as histone acetyltrans-
ferases (HATs†), histone deacetylases (HDACs), histone
kinases and methyltransferases, as well as ATP-depen-
dent chromatin remodeling complexes [1]. These factors
regulate gene expression by altering the conformation of
DNA and allowing access to key regulatory elements of
transcription. Transcription factors bind to specific reg-
ulatory sequences in the DNA and regulate transcription
of the associated gene by promoting recruitment of the
transcription initiation machinery. Additionally, tran-
scription factors are capable of directing histone modi-
fying enzymes and chromatin remodeling complexes to
specific sites, such as gene promoters, thus preparing the
gene for transcription or, in the case of repressors, block-
ing it.
Transcription factors interact in a combinatorial
fashion to uniquely regulate genes and, in response to dif-
ferent stimuli, regulate tissue-specific and developmen-
tal stage-specific gene expression. Many transcription
factors are expressed in a tissue-specific manner and reg-
ulate the specialized functions of a particular cell; there-
fore elimination of these factors can result in a block in
development/differentiation. For example, SCL/TAL1 is
a crucial transcription factor in the hematopoietic system
and the deletion of its gene in mice results in a failure to
generate hematopoietic precursors and embryonic death
[2]. Other transcription factors are ubiquitously expressed
and are generally involved in the expression of ubiqui-
tously expressed “housekeeping” genes in all cell types.
However, they can also interact with tissue-specific pro-
teins or be post-translationally modified in a tissue-spe-
cific manner to elicit a particular pattern of gene
expression. Nuclear Factor I (NFI) family members are
ubiquitously expressed and are involved in the regulation
of constitutive genes and those that are controlled by hor-
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RevIeW
Sp1 belongs to the 26 member strong Sp/KLF family of transcription factors. It is a paradigm for a ubiqui-
tously expressed transcription factor and is involved in regulating the expression of genes associated with a
wide range of cellular processes in mammalian cells. Sp1 can interact with a range of proteins, including
other transcription factors, members of the transcription initiation complex and epigenetic regulators, en-
abling tight regulation of its target genes. In this review, we discuss the mechanisms involved in Sp1-medi-
ated transcriptional regulation, as well as how a ubiquitous transcription factor can be involved in
establishing a tissue-specific pattern of gene expression and mechanisms by which its activity may be regu-
lated. We also consider the role of Sp1 in human diseases, such as cancer.
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monal, nutritional, and developmental signaling [3]. How-
ever, the knockout of individual NFI members results in
tissue-specific defects. For example, NFI-A knockout
mice have a defect in brain development (formation of the
corpus callosum) but few other anatomical problems [4].
This suggests that the four NFI family members have
overlapping roles and can compensate for the lack of NFI-
A activity, but there are distinct functions in specific tis-
sues, revealed by the defects, indicating ubiquitous
transcription factors have important roles in development
and tissue-specific gene expression. Conversely, knock-
out of the gene encoding OCT1, another ubiquitously ex-
pressed transcription factor, leads to developmental arrest
at a very early embryonic stage [5], suggesting widespread
roles. Although OCT1 is important in the expression of
housekeeping genes, such as H2B [6], it also activates tis-
sue-specific genes, often via interactions with cell-specific
proteins [7-9]. The IL3 locus is an example of such a tar-
get. T Cell Receptor signaling leads to activation of an in-
ducible T cell-specific enhancer upstream of the IL3 gene,
containing NFAT and OCT1 binding sites. Studies have
shown the two transcription factors interact at the en-
hancer to synergistically activate T cell-specific IL3 ex-
pression [8]. Importantly, this system demonstrates how
cooperation with a cell-specific protein can alter the bind-
ing or the activity of a ubiquitous transcription factor to
bring about tissue-specific gene expression.
Sp1 is a transcription factor that has been found to be
present in all mammalian cell types [10]. Thus, it was long
thought to be solely a regulator of housekeeping genes and
indeed, knockout of Sp1 in mice causes embryonic lethal-
ity at an early stage of development (around day 10.5 of
gestation) with a broad range of phenotypic abnormali-
ties, suggesting a general function in many cell types [11].
However, Sp1 is now also known to be involved in the
regulation of tissue-specific, cell cycle, and signaling path-
way response genes [12], with chromosome mapping
studies estimating there are at least 12,000 Sp1 binding
sites in the human genome, associated with genes involved
in most cellular processes [13]. Furthermore, its expres-
sion levels were seen to vary in different cell types and
through different stages of mouse development [14], and
it is required for the transcriptional activation of Hsp70.1,
one of the first genes expressed after fertilization in mouse
embryos [15], highlighting Sp1’s importance in develop-
ment. It has also been shown to play a role in numerous
human diseases, including cancer. Therefore, it is impor-
tant to fully understand Sp1’s mode of action and contri-
bution to gene regulation.
THE SP/KLF FAMILY
Sp1 was the first mammalian transcription factor to
be cloned and characterized, named originally according
to the purification procedure used (Sephacryl and phos-
phocellulose columns), but now more commonly named
Specificity protein 1 [16,17]. When whole cell extracts
were prepared from HeLa cells to study the factors re-
quired for transcription initiation in vitro, Dynan and Tjian
identified that one of these factors, Sp1, showed sequence
specificity and was able to bind to the Sv40 early pro-
moter and activate transcription of the gene [18].
Sp1 is the founding member of the Specificity pro-
tein/Krüppel-like factor (Sp/KLF) family of transcription
factors, which currently has a total of 26 members [19].
The family is characterized by the highly conserved DNA
binding domain (sequence identity > 65 percent) near to
the C-terminus of all members, which recognize GC (con-
sensus sequence: GGGGCGGGG), as well as GT/CACC
(GGTGTGGGG) boxes [16,20-22]. The DNA binding do-
main is made up of three adjacent Cys2His2-type zinc fin-
gers consisting of exactly 81 amino acids in every protein
[17]. Not only are the amino acids within the individual
zinc finger structures conserved, but there are also con-
straints on the residues in the interfinger regions, with the
conserved linker sequence T/S-G-Q-R/K-P, suggesting
the zinc fingers act as a single unit [23]. The residues that
are directly in contact with the DNA, and therefore pro-
viding the specific base recognition, are the most con-
served parts of the protein. In Sp1, these residues were
identified as KHA in the first zinc finger, ReR in the sec-
ond and RHK in the third, although there are slight
changes in some of the other family members that corre-
spond with differing preference to GT boxes rather than
GC boxes, or differing binding affinities [16,24].
The Sp/KLF family is split into two groups based on
the structure at the N-terminus: Sp-like transcription fac-
tors (Sp1-9) (Figure 1) and the KLF-like transcription fac-
tors, named from the Cys2His2 zinc finger Krüppel
protein in Drosophila. In general, the Sp-like family rec-
ognize GC boxes in preference to GT boxes, while the re-
verse is found for the KLF-like family, which comprises
both transcriptional activator and repressor proteins. In
terms of structure, the nine Sp-like members are distin-
guished from the KLF-like proteins by the presence of a
conserved Buttonhead domain (BTD, first identified in the
Drosophila Sp1 homologue Buttonhead) N-terminal to the
DNA binding domain [23,25]. Its function is debated, but
studies suggest it is involved in the transactivation or syn-
ergistic activities of the Sp proteins [26,27]. Another fea-
ture in most Sp-like proteins is a conserved stretch of
amino acids at the N-terminus of the protein with the se-
quence SPLALLAATCSR/KI, termed the Sp box [23].
Again, the precise function of this motif is unknown, but
as it contains an endoproteolytic cleavage site and is lo-
cated close to the region in Sp1 that targets proteasome-
dependent cleavage [28], one theory is that it may have a
function in regulation of protein degradation.
The Sp-like protein family can be further subdivided
into Sp1-4 and Sp5-9, with Sp1-4 being distinguishable
by the presence of N-terminal glutamine-rich transcrip-
tional activation domains. Overall, Sp1-4 have a very sim-
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ilar modular domain structure with Sp1, Sp3 and Sp4
being more closely related in structure and activity than
Sp2. The former proteins have a highly conserved DNA
binding domain sequence and bind to GC boxes (and to a
lesser extent, GT boxes) with similar affinities. Sp2, how-
ever, preferentially binds GT boxes due to changes from
the consensus zinc finger DNA-binding residues, with a
leucine substituted for the conserved histidine residue in
the first zinc finger [21,29]. Sp1, Sp3, and Sp4 each con-
tain two glutamine-rich transactivation domains, termed
A and B, located near to a serine/threonine-rich sequence,
which is the target of many posttranslational modifica-
tions. Sp2, on the other hand, only contains one glutamine-
rich domain, but they share a highly charged region
adjacent to the DNA binding domain (domain C) [21].
Both Sp1 and Sp3 are ubiquitously expressed in
mammalian cells. They have highly similar structures,
with their DNA binding domains sharing over 90 percent
DNA sequence homology, meaning that the two tran-
scription factors recognize the same DNA sequence ele-
ment and bind with similar affinity [21,30]. However,
while knockout of Sp1 in mice causes death at around day
10.5 of gestation [11], Sp3 knockout mice die postnatal,
apparently of respiratory failure [31,32]. In addition, mice
heterozygous for either transcription factor appear normal,
albeit slightly smaller, but being heterozygous for both
proteins leads to embryonic lethality with a diverse range
of phenotypes [32]. This suggests that, despite having very
similar DNA specificity and affinity, the two transcription
factors perform distinct functions in the cell. In support,
high resolution fluorescent microscopy studying im-
munolocalization of Sp1 and Sp3 in the MCF-7 cell line
revealed that both proteins were concentrated in discrete
regions of the nucleus and are part of different promoter
complexes [33]. However, the expression of many Sp tar-
get genes in Sp1-/- mice was found to be unaffected, sug-
gesting that Sp3 may be able to compensate, in part, for
loss of Sp1-mediated transcription and thus there is po-
tential redundancy between Sp1 and Sp3 functions [11].
The biggest differences between the structures of Sp1
and Sp3 are a) the presence of a domain D at the C-termi-
nal end of Sp1 only (important for synergy and multimer-
ization, see below) [34] and b) the position of the
inhibitory domain, which suppresses the transcription ac-
tivation potential. In Sp1, the inhibitory domain is located
at the N-terminus and acts by interacting with co-repres-
sor molecules [35], while in Sp3, it is positioned just N-
terminal to the three zinc fingers [36]. Transfection of Sp3
into Drosophila SL2 cells showed that it could only acti-
vate a portion of Sp target promoters and could not acti-
vate reporter gene constructs [37]. Mutation analysis
identified the inhibitory domain, which worked to silence
the two transactivation domains, and highlighted the im-
portance of a highly charged amino acid motif ‘Kee’ for
inhibitory behavior. Mutation of the Kee motif to alanine
residues converted Sp3 into a strong transcriptional acti-
vator, identifying a means by which Sp3 activity could be
regulated [36]. It is theorized that these structural differ-
ences are responsible for the functional differences of Sp1
and Sp3 [29,31].
The functions of other Sp proteins have also been
studied. expression of Sp2 is detectable in embryonic
stem cells (eSCs) and in all tissues during embryogenesis
(except the heart). It was initially found to be unable to
stimulate transcription from promoters that are activated
by other Sp members [38], but knockout of Sp2 in mice
led to embryonic death at day 9.5, showing it is an essen-
tial transcription factor in mouse development [39]. Sp4
knockout mice show no obvious abnormalities, but two
thirds die within their first month and the surviving mice
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Figure 1. Primary structure of the Sp-like transcription factors.
Conserved domains of the Sp-like transcription factors are illustrated. Two glutamine (Q)-rich domains (A and B) form
the transactivation domains, while the inhibitory domains (ID) present in Sp1 and Sp3 are also indicated. Three zinc
fingers at the C-terminus comprise the DNA binding domain and domain C contains a highly charged region adjacent
to the DNA binding domain. Domain D in Sp1 enables synergistic binding with other Sp1 proteins. The conserved se-
quence motifs, BTD and Sp boxes, are also shown and the length of the protein in amino acids is indicated on the
right.
are smaller in size with abnormal reproductive organs
[40,41]. Overall, Sp4 knockout studies suggest that the
transcription factor is required for specification of the car-
diac conduction system [42] and normal brain develop-
ment [43]. Knockout of members of the KLF family have
also been found to be embryonic lethal (KLF1, 2, 5 and 6),
with the others displaying abnormalities in a range of tis-
sues [44]. These deletion studies show the importance of
the Sp/KLF transcription factors, while the variety of phe-




The Sp-like family of transcription factors generally
function to activate transcription, whereas the KLF-like
subgroup contains both activators and repressors of gene
expression. Sp1 functions by recruiting the basal tran-
scription machinery and, specifically, interacting with
members of the TFiiD complex. TFiiD is composed of the
TATA-binding protein (TBP) and multiple TBP-associ-
ated factors (TAFs). It is the first component of the tran-
scription machinery to bind to the promoter, which then
triggers formation of the pre-initiation complex. These in-
teractions are known to be regulated by various transcrip-
tion activators [45]. An in vitro transcription system first
revealed that TFiiD was necessary and sufficient for Sp1
mediated transcription [46]. Characterization of the com-
ponents of the TFiiD complex showed that the Drosophila
protein dTAFii110 (the human homologue is hTAFii130)
contained both glutamine- and serine/threonine-rich do-
mains, similar to that of Sp1, leading to the hypothesis that
the two proteins were functionally linked. Indeed, a yeast
two hybrid assay demonstrated interactions between the
transactivation domains of Sp1 and the N-terminus of
dTAFii110, and transcription activation by Sp1 was in-
creased with the addition of the dTAFii110 N-terminal
fragment [46]. Deletion mutants revealed that each Sp1
transactivation domain interacts with distinct regions of
hTAFii130. Of the four glutamine-rich domains (Q1 to
Q4) within hTAFii130, the interaction with transactiva-
tion domain B of Sp1 was only disrupted upon deletion of
Q1, whereas transactivation domain A made multiple con-
tacts to hTAFii130 at Q2, Q3 and Q4 [47]. Interestingly,
it was found that it was the hydrophobic residues within
the transactivation domains that were important for the
binding to dTAFii110 and subsequent transcription acti-
vation, whereas mutation of the glutamine residues had no
effect [48]. These studies were then followed by the dis-
covery that Sp1 also binds to TBP with the interaction oc-
curring via the Sp1 glutamine-rich transactivation
domains and the conserved C-terminus of TBP. There was
a correlation between the extent of binding and the level
of transcription in vitro, but TBP alone was not sufficient
to activate Sp1-mediated transcription [45]. Therefore,
Sp1 regulates transcription by communication with the
RNA polymerase II transcription machinery.
Sp1 also regulates gene expression by affecting the
chromatin state. It has been found to interact with histone
modifying enzymes, including the HAT p300 [1,49]. The
interaction between the DNA binding domain of Sp1 and
the acetyltransferase catalytic domain of p300 leads to in-
creased binding of Sp1 to DNA. Despite the DNA binding
domain of Sp1 being acetylated by p300 during the inter-
action, there was little effect on DNA binding under vary-
ing acetylation conditions, suggesting that the increase in
DNA binding was due to the direct interaction of the two
proteins [49]. Thus, gene expression can be promoted both
by changing the chromatin modifications at the promoter
towards a more permissive structure and by the binding
of a transcription activator, in this case Sp1. DNA binding
of Sp1 then causes a release of p300, allowing it to regu-
late expression at further genes [49]. An example of co-
operation between Sp1 and p300 is found during neuronal
differentiation (in response to nerve growth factor signal-
ing) when they activate the p21 promoter to bring about
withdrawal of the progenitor neural cells from the cell
cycle [50].
Sp1 can also interact with negative epigenetic modi-
fiers to cause down-regulation of gene expression [12,33].
Trichostatin A, an HDAC inhibitor molecule, was shown
to lead to activation of the Thymidine Kinase (TK) gene.
This gene is a target of Sp1 and indeed, co-immunopre-
cipitation experiments showed HDAC1 and Sp1 to be part
of the same complex with interactions occurring via the
C-terminal DNA binding domain of Sp1. The presence of
Sp1 was also required for HDAC1-mediated TK repres-
sion, showing that Sp1 is involved in HDAC-mediated
transcription inhibition [51]. HDAC1 was similarly found
to be associated with Sp1 at the p21 promoter in prolifer-
ating cells, so regulating cell cycle progression [52]. In
addition, the DNA methyltransferase DNMT1 was found
to bind to Sp1 and elicit repression of some Sp1 target
genes, such as MAZ [53]. DNMT1 bound to seven con-
sensus amino acids in the N-terminus of Sp1 and, at the
Survivin promoter, were found to act together to inhibit
gene expression (in response to p53 signaling and cell
stress). In addition, Sp1 gradually recruited other tran-
scriptional repressors, such as HDAC1 [54], to control
gene expression in response to changing cell conditions. In
contrast, Sp1 is involved in the maintenance of a methy-
lation free state at the CpG islands in target gene promot-
ers, for example at the APRT gene [55,56]. The
methylation free CpG islands on APRT corresponded to
three GC boxes, which footprinting revealed were bound
by Sp1. The promoter region became methylated upon
deletion or mutagenesis of the Sp1 binding sites, suggest-
ing that Sp1 sites are required for the maintenance of CpG
islands and the activation of gene expression [56]. Simi-
lar interactions with epigenetic regulators have also been
reported for Sp3 [57-59].
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Sp1 is capable of synergistically activating transcrip-
tion [60]. early studies involving co-transfection of an Sp1
expression vector and reporter constructs in Drosophila
SL2 cells showed that while one Sp binding site gave
modest activation of the reporter gene, two sites produced
78-fold greater transcriptional activation [34]. Similar ex-
periments also demonstrated the ability of Sp1 to activate
transcription from both proximal and distal sites (using re-
porter constructs containing sites near the transcription
start site or 1.7 kb away), with the presence of both sites
eliciting efficient and strong activation of transcription
[61]. electron microscopy revealed that this synergistic
activation between proximal and distal sites was achieved
through looping of the intervening DNA to allow Sp1 pro-
tein interactions [62]. The ability of Sp1 to regulate loop-
ing of DNA between enhancers and promoters was more
recently confirmed using chromosome conformation cap-
ture assays [63]. Furthermore, crosslinking showed that
there were interactions between individual Sp1 proteins,
with dimers, trimers and tetramers forming both in solu-
tion and bound to DNA [34,61]. Additional electron mi-
croscopy studies imaged Sp1 as initially forming a
tetramer at the promoter site. Upon DNA looping it as-
sembled into multiple tetramers with those at the distal el-
ement at the DNA loop junction [64]. This suggests that
transcriptional synergy occurs through interaction of Sp1
monomers to form multimer complexes at regulatory ele-
ments. Using eMSA and titration of Sp1 protein, it was
demonstrated that Sp1 bound initially as a monomer until
most of the free DNA template was occupied, followed
by a second Sp1 molecule with increasing protein con-
centration [34]. This shows that the increase in transcrip-
tion activation is not due to cooperative binding between
Sp1 molecules, but rather to synergism, i.e. they do not
affect each other’s DNA binding affinity, but together can
activate transcription to a greater extent than the sum of
each alone.
Deletion analysis of the distinct domains of Sp1 re-
vealed that, in addition to the transactivation domains A
and B, the C-terminal domain D is required for multimer
formation and synergistic transactivation [34]. The do-
main D deficient Sp1 mutant was able to activate tran-
scription with equal efficiency to wildtype at promoters
with a single GC site, but there was a decreased transacti-
vation at promoters with multiple binding sites [61]. For
example, the p21 promoter contains 6 GC boxes and a
deletion of domain D in Sp1 gave just a 12-fold increase
in transcription of p21, in contrast to a 47-fold increase
with wildtype Sp1 [65], indicating domain D is required
for synergy. Further analysis of the Sp1 domain structure
reported that a form of Sp1 unable to bind DNA (missing
the zinc finger domain) had no transcriptional activity
when expressed alone in SL2 cells, but could interact with
a DNA-bound wild type Sp1 protein and significantly en-
hance transcription, showing superactivation of Sp1 me-
diated transcription [34,61].
As most members of the Sp/KLF family have similar
DNA sequence specificity, yet varying transcriptional
stimulation activities, the relative levels of expression of
each member in the cell can influence the gene expression
pattern [66]. The ratio of Sp1 and Sp3 levels in the cell is
particularly important due to their highly similar, indeed
almost identical, DNA binding specificity and affinity
[21,37]. The relevance of the ratio of the two proteins was
highlighted in primary keratinocytes, in which Sp3 levels
exceed those of Sp1. However, upon differentiation of the
cells in vitro, Sp1 levels increase and the Sp3/Sp1 ratio is
inverted, suggesting that Sp1 and Sp3 are differentially in-
volved in the regulation of transcription of some cell type-
specific genes [29,67]. Sp1 and Sp3 can both cooperate to
synergistically activate transcription, such as at the tumor
suppressor gene RASSF1A [68] and transactivate genes in-
dependently, e.g. the gene encoding prostate-specific anti-
gen [68]. However, this is still a contentious issue, as the
theory that Sp1 and Sp3 cooperate to regulate transcription
is contradictory to findings that Sp1 and Sp3 are present
in distinct transcription complexes [33].
early studies into Sp3 activity reported that Sp3 was
not able to initiate expression of several genes with dif-
ferent Sp site-containing promoter elements in Drosophila
SL2 cells [37]. In fact, Sp3 could repress Sp1 mediated
transcription in this system. The repression was dependent
on the DNA binding domain, suggesting Sp3 functioned
through competition with Sp1 at Sp recognition sites [37].
In light of such studies, it was first thought that Sp3 func-
tioned as a transcriptional repressor molecule. However,
co-transfection of Sp1 and Sp3 expression vectors with a
number of different Sp1 target genes revealed that only
the promoters consisting of multiple GC/GT boxes were
subject to Sp3 mediated repression of Sp1 transcription
[70]. The ability of Sp3 to repress transcription was found
to be due to both the C terminal inhibitory domain (as dis-
cussed above) [36] and that Sp3 cannot transactivate syn-
ergistically at two or more Sp binding sites [30,71].
Despite Sp3 binding to DNA as a monomer, it can form
highly stable complexes with those proteins at nearby Sp
recognition sites, which are slower to dissociate than ei-
ther monomeric Sp3-DNA or multimeric Sp1-DNA com-
plexes. This means Sp3 can outcompete Sp1 for binding
at promoters consisting of multiple Sp sites. Moreover,
Sp3’s inhibitory domain and lack of a domain D like Sp1
means that Sp3 cannot synergistically activate transcrip-
tion. Thus, when Sp3 displaces the stronger transactiva-
tor Sp1 at a regulatory element, there is a net repression of
Sp1-mediated transcription [30,60]. This is exemplified
by co-transfection studies in Drosophila: Sp1 can give
about 100 fold increase in BCAT2 expression, whose pro-
moter has multiple GC boxes, whereas there is only a
slight increase with Sp3 [30]. Therefore, the differential
expression of different transcription factors and their in-
terplay is important for determining the specific gene ex-
pression pattern of a cell.
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SP1 REGULATION
While Sp1 is active in all cell types and conditions, it
is also tightly regulated enabling Sp1 activity to alter in
response to signaling pathways and changing cellular con-
ditions, giving differential expression of inducible and cell
cycle/growth genes (including many tumor suppressor
genes and oncogenes). One such mechanism is through
interactions with other proteins. Transcription factors in-
teract to generate unique patterns of gene expression,
meaning the cell can function with a relatively small num-
ber of transcription factor proteins. Sp1 has a variety of
binding partners dependent on the cell conditions and ex-
tracellular signals, which regulate Sp1-dependent tran-
scription [60,72]. Some proteins can bind and enhance
Sp1 activity. Oct1, for example, was found to interact with
domain B and the adjacent serine/threonine-rich region of
Sp1 and increase its DNA binding affinity by coopera-
tively binding to the distal regulatory element of the U2
snRNA gene to increase transcription [73]. Other proteins
can bind to Sp1 and activate transcription synergistically,
such as estrogen receptor (eR) proteins. eR binding to
Sp1 increases Sp1-DNA binding to estrogen responsive
elements independently of estrogen, but the transactiva-
tion of the gene is only enhanced in the presence of estro-
gen [74], illustrating how Sp1-mediated transcription can
be altered to respond to signaling pathways. Alternatively,
transcription factors can superactivate Sp1-dependent
transcription by interacting with DNA-bound Sp1, but not
binding to DNA directly, for example AP2, first shown
using GAL4 transactivation assays [75].
There are also examples of protein-protein interac-
tions mediating negative effects on Sp1 activity. The cell
cycle regulator p53 can bind to Sp1 and interfere with its
binding to the hTERT promoter (encoding the human
telomerase reverse transcriptase gene), thus preventing ex-
pression and contributing to tumor suppression [76]. Al-
ternatively, p53 can inhibit expression of the cyclin B1
gene without interfering with Sp1 binding: the inhibition
of cyclin B1 was dependent on the Sp1 binding sites and
an Sp1/p53 complex was identified at the promoter. How-
ever, p53 did not bind the DNA directly, suggesting the in-
hibition was not through competition/preventing DNA
binding, but possibly by disruption of the recruitment of
transcription machinery [77]. Conversely, p53 can interact
with Sp1 to positively regulate transcription at the p21
promoter. In proliferating cells, the p21 promoter is in-
hibited by HDAC1 binding to Sp1 at the promoter, but
upon cell stress and p53 induction, p53 displaces HDAC1
from Sp1 to activate p21 transcription and halt the cell
cycle [52,78].
Sp1 is also highly post-translationally modified, al-
tering Sp1 activity and enabling specific responses to a
range of signals. One of the most well studied post-trans-
lational modifications of Sp1 is phosphorylation. There
are thought to be 23 putative phosphorylation sites in Sp1
and various kinases have been identified, resulting in di-
verse functional effects [79,80]. Most kinases affect the
DNA binding of Sp1, for example, Cyclin B1-Cdk phos-
phorylates Sp1 at T739 at the C-terminus during mitosis,
causing reduced Sp1 DNA binding and facilitating chro-
matin condensation [81]. In contrast, phosphorylation of
S59 at the Sp1 N-terminus by cyclin A-Cdk leads to in-
creased DNA binding and transcription [82]. It can also
impact on Sp1 protein stability. During mitosis, JNK
phosphorylates T278 and T739, however, with kinase in-
hibitors to target JNK, Sp1 becomes ubiquitinated and
proteasomally degraded [83]. The phosphorylation at
T739 was shown to prevent binding to the e3 ubiquitin
ligase, thus shielding Sp1 from degradation during mito-
sis and maintaining levels for cell cycle progression [84].
In addition, Sp1 can be acetylated at K703 in the
DNA binding domain, which is linked to its interactions
with HAT and HDAC epigenetic regulators. As described
above, p300 increases Sp1 binding to DNA, albeit inde-
pendently of acetylation of Sp1 [49], but acetylation at
K703 by p300 reduces their interaction and so decreases
the Sp1 transcriptional activity [85]. Sp1 can also be
deacetylated by HDAC1, which increases its binding to
promoters important for cell cycle and cell death, such as
p21 and Bak [86]. Furthermore, Sp1 undergoes various
other post-translational modifications, including glycosy-
lation [87,88], poly(ADP-ribosyl)ation [89], methylation
[90] and sumoylation [91], which, along with phosphory-
lation and acetylation modifications, are extensively re-
viewed in Chu, 2012 [92] and Chang and Hung, 2012
[79].
More recently, several miRNAs have been identified
which can post-transcriptionally modulate Sp1 expression,
thus providing an additional level of regulation. examples
of such miRNAs are discussed below and reviewed in
Safe, 2015 [93]. Together, these different aspects of reg-
ulation allow a ubiquitous factor, such as Sp1, to carry out
diverse functions in a wide range of cell types.
TISSUE-SPECIFIC ROLES OF SP1
A common theme in gene regulation is the coopera-
tion of ubiquitous transcription factors (including Sp1)
with tissue/development stage-specific transcription fac-
tors. Much of the research into this mechanism has been
performed in the hematopoietic system, one of the most
widely studied differentiation systems. Indeed, levels of
Sp1 were shown to be high in hematopoietic cells in the
mouse embryo [14] and Sp binding sites were identified at
many hematopoietic genes [94]. To trigger activation of
specific gene programs at certain developmental stages or
tissues, Sp1 could either be modified to increase bind-
ing/transactivation at a specific site, or Sp1 could bind at
the site in only that cell type [95]. These two mechanisms
are evident in myeloid differentiation. Firstly, Sp1 under-
goes post-translational modification during myeloid spec-
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ification. The phosphorylated form of Sp1 increases in
myeloid progenitors. This causes increased Sp1 binding
to its target site in the promoter for the CD14 cell surface
protein, thus giving monocyte-specific promoter activity
[96]. Secondly, epigenetic changes could alter the avail-
ability of the binding site. The myeloid transcription fac-
tor Pu.1 binds close to the Sp1 site at the integrin CD11b
promoter. Pu.1 binding exposes the binding site for Sp1 in
the chromatin, allowing it to bind and regulate transcrip-
tion in a tissue-specific manner [97].
In addition, Sp1 can interact with tissue-specific tran-
scription factors to generate tissue-specific gene expres-
sion programs. In erythroid cells, Sp1 can cooperate
synergistically with the transcription factor GATA1 at
erythroid-specific promoters. Sp1 and GATA1 binding
sites can be seen in close proximity at many promoters
and enhancers of erythroid-specific genes. The two pro-
teins physically interact at the DNA binding domains to
synergistically activate transcription, for example at the
EpoR promoter [98], the Tal1 promoter [99] and the
ALAS2 gene (required for heme synthesis), where they
also recruit the activator p300 [100]. Sp1/GATA1 com-
plexes have also been identified at promoters without
GATA sites, suggesting Sp1 can recruit tissue-specific
transcription factors to particular regulatory elements [98].
Furthermore, Sp1 and GATA1 could interact from a dis-
tance in reporter constructs modelling the architecture of
globin locus control regions, suggesting the two proteins
can interact to stabilize loops between regulatory regions
and synergistically activate the globin gene [98].
SCL/TAL1 is an important regulator of hematopoietic
specification. It forms a complex with many other proteins
(e.g. LMO2, Ldb1, e2A), which has been reported to en-
hance Kit expression, encoding a receptor needed in
hematopoiesis. The complex is tethered to the promoter
by Sp1, with the interaction between the cell type-specific
factors and a ubiquitous transcription factor determining
the gene expression profile and cell fate [94]. These stud-
ies also demonstrate that Sp1 can recruit SCL and
GATA1, plus other restricted transcription factors, to spe-
cific promoters, but not to all, indicating that the promoter
architecture is also important in regulation of tissue-spe-
cific genes, likely to position the proteins to enable func-
tional interactions [94].
Despite Sp1 knockout causing embryonic lethality in
mice, Sp1-deficient (with a knockout of the DNA binding
domain) eSCs could grow normally in culture [11]. Dur-
ing in vitro differentiation to mimic embryonic
hematopoiesis in culture, Sp1-deficient embryonic stem
cells could proceed through most stages of blood cell de-
velopment, but Sp1 was required for terminal differentia-
tion. Gene expression analysis of purified cells
representing successive stages of hematopoietic specifi-
cation revealed a progressive deregulation of gene ex-
pression: most Sp1 target genes were unaffected, but Cdx
and some Hox genes were downregulated at an early
stage, and the number of affected genes increased through
later stages as a result, causing a failure in terminal
hematopoietic differentiation. Interestingly, the deletion
of Sp1 at later developmental stages, in this case at the
myeloid progenitor stage had no effect, indicating that the
defects in the Sp1 knockout mice were cumulative [101]. 
Additional tissue- and developmental-specific roles
have been discovered for Sp1 and other Sp factors, in-
cluding in the nervous system. The NR1 gene encodes an
essential component of the N-methyl-D-aspartate recep-
tor, which is important for neuronal differentiation. Sp fac-
tors bind to and activate an NFκB site in the promoter to
upregulate NR1 expression: specifically Sp3 during neu-
ronal differentiation and Sp1 in differentiated neuronal
cells [102]. Sp1, Sp3 and Sp4 interact to activate neuronal-
specific transcription of cyclin-dependent kinase 5/p35,
which is critical for brain function [103]. However, Sp3
and Sp4 together repress expression of superoxide dis-
mutase 2 in neurons, but the substitution of Sp4 for Sp1 in
astroglia causes upregulation of transcription [104]. More-
over, Sp1 and Sp3 mediate expression of cyclooxygenase-
2 in response to oxidative stress in neurons to aid in
neuronal survival [105]. This highlights the importance of
the balance between the levels and activities of related Sp
transcription factors in the function of the nervous system,
particularly the tissue-specific Sp4 and ubiquitous Sp1 and
Sp3.
These examples demonstrate the ability of ubiqui-
tously expressed factors to contribute to lineage specific
regulatory programs and highlights important general
principles in developmentally controlled gene regulation.
SP1 IN DISEASE
Given the role of Sp1 in a multitude of cellular path-
ways and processes, it is unsurprising that it is associated
with the pathogenesis of a number of diseases, with per-
haps the best studied being cancer. Sp1 overexpression is
seen in a host of cancer cell types, where levels of Sp1
also correlate with tumor stage and a poor prognosis [12].
Knockdown of Sp1 in cancer cell lines (including breast,
kidney, pancreatic, lung, and colon cancers) led to de-
creased survival and the inhibition of cell growth and mi-
gration. Similarly, tumor formation and metastasis was
reduced in mouse xenograft models with Sp1 knockdown.
Furthermore, the changes in gene expression following
knockdown correlated with the observed phenotypic
changes of the cells [106]. Indeed, several anticancer
agents in clinical use act by inhibiting Sp1 action [107].
Mithramycin A (and its analogues) can alter the binding of
Sp1 to DNA and downregulate Sp1-mediated transcrip-
tion [108,109]. Tolfenomic acid increases the ubiquitina-
tion and degradation of Sp1 [110], while anthracyclines,
one of the most effective anticancer treatments, bind DNA
at GC-rich sequences, preventing Sp1 binding [111,112],
though this may not be its sole mechanism of action. Other
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drugs can act on Sp1 indirectly, such as curcumin, which
increases reactive oxygen species in the cell, causing ac-
tivation of ZBTB4/10 proteins that displace Sp1 from GC-
rich sites and decreased Sp1 expression [113].
The role of Sp1 in cancer stems from its regulation of
genes that are involved in all of the hallmarks of cancer:
growth factor-independent proliferation, immortality, eva-
sion of apoptosis, angiogenesis, tissue invasion and metas-
tasis [72,114]. Sp1 is involved in the regulation of genes
required for the progression of the cell cycle and entry into
S-phase, such as cyclins and MYC, as well as in growth
factor signaling pathways e.g. IGF1R has up to eight Sp
sites at its promoter and IGF signaling is commonly used
by cancer cells to maintain proliferation [115,116]. How-
ever, it also regulates the transcription of cell cycle in-
hibitor genes, for example, synergizing with p53 under
conditions of cell stress to activate transcription of p21
[65]. Sp1 regulates the expression of telomerase subunits
involved in the maintenance of telomeres and cell im-
mortality. It can bind to five Sp sites present at the hTERT
promoter to activate gene expression [117], or conversely,
interact with HDACs to repress hTERT expression [57].
Sp1 is involved in the control of both pro- and anti-apop-
totic factors, which have a direct role in cancer develop-
ment. Survivin is a protein that promotes cell survival by
inhibiting apoptosis and is essential in many tumors: its
overexpression is directly associated with an increase in
levels of Sp1 [118]. The pro-angiogenic factor veGF has
Sp1 binding sites at its promoter: estrogen signaling in
breast cancer can result in interaction of Sp1 with eRα
and subsequent upregulation of the VEGF gene [119]. Sp1
is also involved in maintaining genome stability via reg-
ulation of DNA damage factors and inflammatory signal-
ing to drive oncogenesis [72].
While the deregulation of signaling pathways and
transcription factor networks has been well studied, the
impact of aberrantly expressed miRNAs in cancer is a
newly developing field. Specific miRNAs have been
found to be downregulated in certain cancers, such as
miRNA223 in gastric cancer [120]. In this example, Sp1
protein levels were also found to increase, but with no
change in mRNA levels, suggesting post-transcriptional
regulation. miRNA223 was found to bind to the 3’ un-
translated region of Sp1 mRNA and inhibit its translation.
The increase in Sp1 led to enhanced epithelial-mesenchy-
mal transition (eMT), involved in promoting cell migra-
tion and invasion in tumorigenesis, whereas
overexpression of miRNA-223 in a gastric cancer model
caused decreased eMT and proliferation, and induced
apoptosis [120]. A similar action was discovered for
miRNA-324-5p in Hepatocellular carcinoma (HCC) [121]
and miRNA-23b in multiple myeloma [122]. Addition-
ally, Sp1 has been found to regulate the expression of
miRNAs. miRNA-195 promotes cell apoptosis and sup-
presses cancer cell proliferation/metastasis; its expression
is frequently reduced in various cancers. Characterization
of its promoter region found an Sp1 site required for
miRNA-195 expression, but in HCC cells, Sp1 interacted
with HDAC3 at the promoter to repress transcription
[123]. The miRNA-23a-27a-24-2 cluster is deregulated in
many cancers. The promoter, containing 2 Sp1 sites, was
found to be demethylated in Hep2 cells, compared to con-
trol HeK293 cells, leading to upregulation of the cluster
and promotion of proliferation and cell survival of cancer
cells [124]. Furthermore, Sp1 was found to be involved in
a regulatory network with another transcription factor
(NFκB), an epigenetic regulator (HDAC) and a miRNA
(miRNA-29b) to modulate KIT expression in a subset of
acute myeloid leukemia (AML) [125]. miRNA-29b acts
to post-transcriptionally inhibit Sp1. Conversely, Sp1,
along with NFκB, binds to the miRNA-29b enhancer and
interacts with HDAC1/3 to form a repressive complex and
inhibit miRNA-29b expression. Aberrant activation of KIT
in AML cells leads to upregulation of MYC, which in turn
results in downregulation of miRNA-29b and an increase
in Sp1 expression. Sp1, along with NFκB, activates KIT
transcription, thus completing the regulatory loop and con-
tributing to the disease state [125].
Sp1 can be linked to the changes in DNA methyla-
tion often observed in cancer cells. Sp1 can be involved in
the protection of regulatory regions of genes (especially
housekeeping genes) from methylation [55,56] and when
methylation spreads to Sp1 sites, binding is inhibited, con-
tributing to gene silencing [126]. Sp1 mediates transcrip-
tion of the tumor suppressor RASSF1A, whose promoter
has four Sp sites. In cancer, a change in histone modifica-
tions (H3 deacetylation and K9 trimethylation) causes a
reduction in Sp1 binding, followed by methylation of the
promoter and gene silencing [127]. This suggests that the
increase in Sp1 levels in cancer cells is not sufficient to
overcome the silencing of its target genes through DNA
methylation. However, Sp1 can also interact with DNMT1
to promote methylation at specific sites [53,54], suggest-
ing a role for Sp1 in establishing the epigenetic state of
both normal and cancer cells. More studies are needed to
completely understand its mechanism in transcription ac-
tivation and epigenetics. The ability of Sp1 to regulate
oncogenes and tumor suppressors, pro-survival and pro-
apoptotic genes, highlights the need to fully understand
Sp1’s activity at different promoters and in different cell
conditions to develop a therapy that can specifically target
Sp1 in cancer.
Sp1 has been implicated in Huntington’s disease, a
dominantly inherited neurodegenerative disorder caused
by expansion of a polyglutamine tract in the Huntingtin
(Htt) protein. Htt was found to bind to Sp1 and TAFII130
and inhibit DNA binding, while overexpression of both
factors in striatal cells from a mouse model of Hunting-
ton’s led to an improvement of symptoms and reversed
inhibition of the dopamine D2 receptor gene, known to be
a marker of the disease [128]. Further studies suggested
the protective role of Sp1 overexpression involved acti-
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vation of cystathione γ-lyase gene expression, the biosyn-
thetic enzyme for cysteine, which is depleted in disease
tissues [129]. However, this issue is still disputed, as other
studies have found Sp1 contributes to the pathology in
Huntington’s disease. Sp1 was found to be overexpressed
in the brains of mouse models and in model cell lines: in-
hibition or knockout of Sp1 led to amelioration of toxic-
ity caused by mutant Htt and the mice survived longer,
possibly due to Sp1 negatively regulating the Dopamine
D2 gene. This suggests Sp1 is a potential therapeutic tar-
get in Huntington’s disease [130].
A positive role of Sp1 has been found in Alzheimer’s
disease, where inhibition of Sp1 with mithramycin A in
transgenic mouse models led to further memory impair-
ment and an increase in the levels of Amyloidβ peptides
(a major hallmark of the disease) [131]. A polymorphism
in an Sp1 binding site of the COL1A1 gene, encoding
collagenα1, a major protein in bone, is associated with a
predisposition to osteoporosis by altering the ratio of col-
lagen α1 to α2 chains, causing reduced biomechanic
strength in the bones [132]. In contrast, there was a nega-
tive correlation between the same polymorphism and hip
osteoarthritis, suggesting there is a reduced risk of the dis-
ease [133]. Furthermore, Sp1 has been implicated in the
development of multiple sclerosis (MS). Polymorphisms
in the IRF5 and CD24 genes, factors involved in MS, can
lead to increased Sp1 binding at these genes and an in-
creased risk of MS [134,135]. Gene expression analysis
in MS patients suggested the involvement of Sp1 in gen-
der-specific gene signatures and inhibition of Sp1 tran-
scription reduced the incidence and severity of
experimental autoimmune encephalomyelitis in mice (the
model of MS), highlighting Sp1 as a potential therapeutic
target in MS [136].
CONCLUSION
Sp1 was the first characterized and still is one of the
best studied mammalian transcription factors. It functions
as a transcriptional activator of a variety of genes includ-
ing house-keeping genes, cell cycle regulators and tissue-
restricted genes. It is ubiquitously expressed, but its
activity can be modified to respond to external stimuli,
different stages of the cell cycle and different cell func-
tions through post-translational modification and interac-
tion with other transcriptional regulators. It can also
regulate tissue- and developmental stage-specific gene ex-
pression, but there is still little known about the protein
interactions and/or post-translational modifications that
occur to elicit the specific patterns of Sp1-mediated gene
expression. Therefore, more work is needed to both fur-
ther understand the role of ubiquitous transcription factors
in tissue-specific gene regulation and the dynamic tran-
scription network controlling cell specification. This re-
view highlights the importance of models of development
to elucidate the mechanism of transcription activation, as
well as the need to further our understanding of Sp1-me-
diated transcription in development and disease.
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